Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc. (Nasdaq: DYNS) filed an 8-K current report with the Securities and Exchange Commission on July 15, 2026, as part of its standard public-company disclosure obligations. The company reached public markets in 2022 through a merger with Dynamics Special Purpose Acquisition Corp, a blank-check vehicle that completed its IPO in 2021 and targeted the biotechnology sector. Senti Biosciences focuses on synthetic biology, specifically engineering gene circuits to direct immune-cell behavior in oncology and other therapeutic areas. For complete filing history, sponsor details, and SPAC-by-SPAC analytics on DYNS and across the market, sign up for full data access on SpacDesk.